CRL News and Press, Charles River Laboratories International Inc. From 03/14/24

Next-generation AAV gene therapy to target debilitating pain disorders Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As pa...

2024-03-09 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-07 12:27:11 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stock markets are reaching new highs and exuberance is in the air. For value investors, this might seem like a perplexing time. However, there are still bargains to be found… outside...

2024-03-07 06:55:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bitcoin ( BTC-USD ) hit a record high of $69,202, topping its previous high of $68,999.99 in November 2021. That’s good news for Coinbase Global (NASDAQ: COIN ...

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use PR Newswire WILMINGTON, Mass. and OKLAHOMA CITY , Feb. 29, 2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile contr...

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Whe...

The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Plurist...

2024-02-16 09:06:59 ET Summary Charles River Laboratories achieved only 6.5% organic revenue growth in FY23 due to weakness in the broader life science industry. CRL offers a comprehensive range of services to pharmaceutical and biopharmaceutical companies, with a broad customer b...

2024-02-14 14:11:46 ET More on Charles River, IQVIA, etc. Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript Medpace Holdings, Inc. (MEDP) Q4 2023 Earnings Call Transcript Medpace Holdings, Inc. 2023 Q4 - Results - Earnings Call Pre...

2024-02-14 13:19:02 ET Charles River Laboratories International, Inc. (CRL) Q4 2023 Results Conference Call February 14, 2024 08:30 AM ET Company Participants Todd Spencer - Vice President of Investor Relations James Foster - President and Chief Executive Officer ...